AU
Peptide research covers a wide range of laboratory work, from analytical chemistry and molecular biology through to early-stage investigations of biological pathways. In Australia, however, it is important to separate laboratory research materials from products that are supplied, promoted or used for therapeutic purposes.
That distinction is not always as simple as the wording printed on a label.
How peptide products are viewed in Australia
The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia. Whether a peptide product falls within this framework depends on factors such as what the product contains, its intended purpose, how it is presented and the claims made about it.
A peptide intended purely for legitimate laboratory investigation may have a different context from a product presented for treating a condition, changing a physiological process or producing another therapeutic outcome.
Researchers and organisations therefore need to consider the actual purpose and circumstances surrounding a material rather than relying on terminology alone.
What does ARTG status mean?
The Australian Register of Therapeutic Goods (ARTG) records therapeutic goods that can generally be lawfully supplied in Australia, subject to the conditions applying to their entry.
Some peptide-based medicines are included in the ARTG for specific therapeutic uses. Other peptide products are not.
Where a product is considered a therapeutic good but is not included in the ARTG, it is generally regarded as an unapproved therapeutic good. The TGA has not assessed such a product for safety, quality or effectiveness.
There are specific pathways through which unapproved therapeutic goods may sometimes be accessed, including clinical trial and other authorised access arrangements. These pathways have their own requirements and should not be confused with ordinary laboratory procurement.
“Research use only” is not a regulatory exemption
This is an important point for Australian laboratories and suppliers.
Describing a material as “research use only” or “not for human use” does not automatically place it outside therapeutic goods regulation. Australian regulators can consider the product as a whole, including its intended use, advertising, presentation and the way it is supplied.
For genuine research materials, documentation should therefore accurately reflect their laboratory purpose rather than making therapeutic or personal-use claims.
Research and therapeutic use are different contexts.
Non-clinical laboratory research should remain clearly separated from human therapeutic use. Analytical testing, method development and controlled experimental work are not the same as supplying a substance for self-administration or treatment.
Clinical research involving unapproved therapeutic goods is also subject to separate Australian requirements. For example, Australian clinical trials involving unapproved therapeutic goods generally operate through the Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) pathways.
Staying within the appropriate framework
Researchers should consider the intended application of a peptide, relevant Commonwealth requirements and any additional state or territory obligations that may apply.
Regulatory requirements can also change. For that reason, laboratories, institutions and suppliers should refer directly to current TGA guidance when determining the requirements applying to a particular material or research activity.
This page provides general regulatory context only and should not be treated as legal, medical or regulatory advice.
